495 related articles for article (PubMed ID: 27775669)
41. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
42. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D; Chinen Y; Isa R; Fujibayashi Y; Kuwahara-Ota S; Yamaguchi J; Takimoto-Shimomura T; Matsumura-Kimoto Y; Tsukamoto T; Shimura Y; Kobayashi T; Horiike S; Taniwaki M; Handa H; Kuroda J
Int J Hematol; 2021 Mar; 113(3):381-394. PubMed ID: 33095415
[TBL] [Abstract][Full Text] [Related]
43. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
44. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
45. Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple myeloma and monoclonal gammopathy of undetermined significance.
Nagoshi H; Taki T; Chinen Y; Tatekawa S; Tsukamoto T; Maegawa S; Yamamoto-Sugitani M; Tsutsumi Y; Kobayashi T; Matsumoto Y; Horiike S; Okuno Y; Fujiwara S; Hata H; Kuroda J; Taniwaki M
Genes Chromosomes Cancer; 2015 Dec; 54(12):788-95. PubMed ID: 26390996
[TBL] [Abstract][Full Text] [Related]
46. Multiple myeloma: is it time for biomarker-driven therapy?
Bhutani M; Landgren O; Usmani SZ
Am Soc Clin Oncol Educ Book; 2015; ():e493-503. PubMed ID: 25993214
[TBL] [Abstract][Full Text] [Related]
47. Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.
Willenbacher W; Seeber A; Steiner N; Willenbacher E; Gatalica Z; Swensen J; Kimbrough J; Vranic S
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30021955
[TBL] [Abstract][Full Text] [Related]
48. Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
[TBL] [Abstract][Full Text] [Related]
49. Genetics: Profiling a shape-shifter.
Humphries C
Nature; 2011 Dec; 480(7377):S50-1. PubMed ID: 22169804
[No Abstract] [Full Text] [Related]
50. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
51. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
[TBL] [Abstract][Full Text] [Related]
52. Recent advances in the management of multiple myeloma.
Kumar L; Verma R; Radhakrishnan VR
Natl Med J India; 2010; 23(4):210-8. PubMed ID: 21192514
[TBL] [Abstract][Full Text] [Related]
53. Multiple myeloma: clinical features and indications for therapy.
Dispenzieri A; Kyle RA
Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
[TBL] [Abstract][Full Text] [Related]
54. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
Chang H; Yeung J; Xu W; Ning Y; Patterson B
Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
[TBL] [Abstract][Full Text] [Related]
55. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
Dezube BJ; Aboulafia DM; Pantanowitz L
AIDS Read; 2004 Jul; 14(7):372-4, 377-9. PubMed ID: 15282866
[TBL] [Abstract][Full Text] [Related]
56. Advances in the diagnosis and management of myeloma.
Greipp PR
Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
[No Abstract] [Full Text] [Related]
57. High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma.
Stevens-Kroef M; Weghuis DO; Croockewit S; Derksen L; Hooijer J; Elidrissi-Zaynoun N; Siepman A; Simons A; Kessel AG
Genes Chromosomes Cancer; 2012 Nov; 51(11):997-1006. PubMed ID: 22833442
[TBL] [Abstract][Full Text] [Related]
58. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
59. Nestin expression throughout multistep pathogenesis of multiple myeloma.
Svachova H; Kryukov F; Kryukova E; Sevcikova S; Nemec P; Greslikova H; Rihova L; Kubiczkova L; Hajek R
Br J Haematol; 2014 Mar; 164(5):701-9. PubMed ID: 24329895
[TBL] [Abstract][Full Text] [Related]
60. Utilizing next-generation sequencing in the management of multiple myeloma.
Lionetti M; Neri A
Expert Rev Mol Diagn; 2017 Jul; 17(7):653-663. PubMed ID: 28524737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
